This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC).
READ FULL ARTICLE
From Mdlinx
According to a new study published in the Journal of Clinical Oncology, researchers have found that weekly docetaxel plus cisplatin is not superior to docetaxel monotherapy as first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC).
For the study, researchers sought to prove that weekly docetaxel and cisplatin demonstrates a survival advantage over docetaxel monotherapy in elderly patients with advanced NSCLC. Researchers enrolled 276 chemotherapy-naive patients with stage III, IV, or recurrent NSCLC (median age 76 years) who were not eligible to receive bolus cisplatin.
Patients were randomly assigned to receive docetaxel 20mg/m2 plus cisplatin 25mg/m2 on days 1, 8, and 15, every 4 weeks, or docetaxel 60mg/m2 on day 1, every 3 weeks. Results showed the median survival times were 13.3 and 14.8 months for the doublet and monotherapy arms, respectively (HR = 1.18; 95% CI: 0.83 - 1.69).
The study was terminated early because an interim analysis demonstrated a predictive probability of 0.996% that the doublet arm would be statistically superior to the monotherapy arm on final analysis.
In regard to safety, grade 3 or higher neutropenia and febrile neutropenia were more common in the monotherapy arm, while anorexia and hyponatremia were more common in the doublet arm.
This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC).
READ FULL ARTICLE
From Mdlinx
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.